Dinoprostone

地诺前列酮

Report date: 2026/01/14 09:47:43
NME

Base Information

Drug NameDinoprostone
Drug Alias Name普洛舒定Dinoprostona地诺前列素 （Pfizer）DinoprostonumProstaglandin E2 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstaglandin E2 receptor agonists
TargetsProstaglandin E2 receptor
Therapy Area/IndicationsContraceptionTerminate pregnancyLabor Pain +[4] 
Global Approved IndicationsTerminate pregnancy
Approved Indications in ChinaTerminate pregnancy
Original Approved Country/TerritoryUnited States
Original Approved Date1977/08/23
Country/TerritoryUnited StatesSaudi ArabiaMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesFerring Controlled Therapeutics LtdKaken Pharmaceutical Co Ltd
Inactive CompaniesCairo UniversityPharmacia & UpjohnAin Shams University
Active IndicationsTerminate pregnancy
Inactive IndicationsContraceptionLabor PainPain

Other Information

ATC CodeG02AD02
Related LinksWikipediaDrugBankKEGG